IMC Chicago LLC Makes New Investment in GoodRx Holdings, Inc. (NASDAQ:GDRX)

IMC Chicago LLC bought a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 65,315 shares of the company’s stock, valued at approximately $304,000.

Other hedge funds have also added to or reduced their stakes in the company. AQR Capital Management LLC boosted its stake in shares of GoodRx by 181.1% during the second quarter. AQR Capital Management LLC now owns 46,159 shares of the company’s stock valued at $360,000 after purchasing an additional 29,741 shares in the last quarter. Vontobel Holding Ltd. boosted its stake in shares of GoodRx by 78.4% during the third quarter. Vontobel Holding Ltd. now owns 93,750 shares of the company’s stock valued at $651,000 after purchasing an additional 41,196 shares in the last quarter. nVerses Capital LLC bought a new position in shares of GoodRx during the third quarter valued at approximately $33,000. Raymond James & Associates boosted its stake in shares of GoodRx by 212.6% during the third quarter. Raymond James & Associates now owns 394,006 shares of the company’s stock valued at $2,734,000 after purchasing an additional 267,951 shares in the last quarter. Finally, CWA Asset Management Group LLC bought a new position in shares of GoodRx during the third quarter valued at approximately $370,000. 63.77% of the stock is currently owned by institutional investors.

GoodRx Trading Down 1.2 %

NASDAQ GDRX opened at $4.83 on Thursday. The company has a fifty day simple moving average of $4.65 and a two-hundred day simple moving average of $6.01. The stock has a market cap of $1.84 billion, a P/E ratio of -161.00, a P/E/G ratio of 2.44 and a beta of 1.28. GoodRx Holdings, Inc. has a 12-month low of $4.09 and a 12-month high of $9.26. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on GDRX shares. KeyCorp dropped their price objective on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Mizuho initiated coverage on shares of GoodRx in a research report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 target price for the company. Morgan Stanley decreased their target price on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 17th. Barclays decreased their target price on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. Finally, Citigroup decreased their target price on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research report on Friday, January 10th. Five equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.38.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.